<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PAROXETINE</span><br/>(par-ox'e-teen)<br/><span class="topboxtradename">Asimia, </span><span class="topboxtradename">Paxil, </span><span class="topboxtradename">Paxil CR<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antidepressant</span>; <span class="classification">selective serotonin reuptake inhibitor (ssri)</span><br/><b>Prototype: </b>Fluoxetine<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 30 mg, 40 mg tablets; 12.5 mg, 25 mg sustained-release tablets; 10 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Antidepressant structurally unrelated to other serotonin reuptake inhibitors. Potent and highly selective inhibitor of serotonin
         reuptake by neurons in CNS.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Efficacious in depression resistant to other antidepressants and in depression complicated by anxiety.</p>
<h1><a name="uses">Uses</a></h1>
<p>Depression, obsessive-compulsive disorders, panic attacks, excessive social anxiety, generalized anxiety, post-traumatic stress
         disorder (PTSD), premenstrual dysphoric disorder (PMDD).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Diabetic neuropathy, myoclonus, bipolar depression in conjunction with lithium, chronic headache, premature ejaculation, fibromyalgia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to paroxetine; concomitant use of MAO inhibitors, pregnancy (category D); alcohol; children or adolescents
         with major depressive disorder.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of mania, suicidal ideation; anorexia nervosa, ECT therapy; seizure disorder, seizures; renal/hepatic impairment,
         renal failure; history of metabolic disorders; volume-depleted patients, recent MI, unstable cardiac disease; lactation. Safety
         and efficacy have not been established in children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1050 mg/d (max: 80 mg/d); 25 mg sustained-release q.d. in morning, may increase by 12.5 mg (max: 62.5 mg/d); use lower
               starting doses for patients with renal or hepatic insufficiency and geriatric patients<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 10 mg/d (12.5 mg/d sustained release),  [max: 40 mg/d (50 mg/d sustained release)]<br/><br/><span class="indicationtitle">Obsessive-Compulsive Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2060 mg/d<br/><br/><span class="indicationtitle">Panic Attacks</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg/d<br/><br/><span class="indicationtitle">Social Anxiety Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2060 mg/d<br/><br/><span class="indicationtitle">Generalized Anxiety, PTSD</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 10 mg once daily, may increase by 10 mg/d at weekly intervals if needed to target dose of 40 mg once daily (max:
               60 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 10 mg PO once daily, may increase by 10 mg/d at weekly intervals if needed (max: 40 mg/d)<br/><br/><span class="indicationtitle">Premenstrual Dysphoric Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12.5 mg once daily (up to 25 mg once daily) throughout the month or daily for 2 wk before menstrual period<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Recommended initial dose with older adult, debilitated, or those with severe renal or hepatic impairment is 10 mg/d.</li>
<li>Ensure that sustained-release form is not chewed or crushed. Must be swallowed whole.</li>
<li>Be aware that at least 14 d should elapse when switching a patient from/to a MAO inhibitor to/from paroxetine.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Postural hypotension. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> tremor, agitation or nervousness, anxiety, paresthesias, dizziness, insomnia, <span class="speceff-common">sedation</span>. <span class="typehead"> GI:</span>
<span class="speceff-common">Nausea,</span> constipation, vomiting, anorexia, diarrhea, dyspepsia, flatulence, increased appetite, taste aversion, <span class="speceff-common">dry mouth</span>. <span class="typehead">Urogenital:</span> Urinary hesitancy or frequency. <span class="typehead">Hepatic:</span> Isolated reports of elevated liver enzymes. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">Skin:</span> Diaphoresis, rash, pruritus. <span class="typehead">Metabolic:</span> Hyponatremia in older adult. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b>Activated charcoal</b> reduces absorption of paroxetine. <b>Cimetidine</b> increases paroxetine levels. <span class="classification">mao inhibitors</span>, <b>selegiline</b> may cause an increased vasopressor response leading to hypertensive crisis or death. <b>Phenytoin</b> can cause liver enzyme induction resulting in lower paroxetine levels and shorter half-life. <b>Warfarin</b> may increase risk of bleeding and <b>thioridazine</b> levels, and prolong QTc interval leading to heart block; increase <b>ergotamine</b> toxicity with <b>dihydroergotamine,</b>
<b>ergotamine.</b>
<span class="typehead">Herbal:</span>
<b>St. John's wort</b> may cause serotonin syndrome (headache, dizziness, sweating, agitation). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 99% absorbed from GI tract. <span class="typehead">Onset:</span> 2 wk. <span class="typehead">Peak:</span> 58 h. <span class="typehead">Distribution:</span> Very lipophilic. 95% protein bound. Distributes into breast milk. <span class="typehead">Metabolism:</span> Extensively metabolized in the liver to inactive metabolites. <span class="typehead">Elimination:</span> Less than 2% is excreted unchanged in urine. Approximately 65% of dose appears in urine as metabolites. Metabolites
      of paroxetine are also excreted in feces, presumably via bile. <span class="typehead">Half-Life:</span> 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for worsening of depression or emergence of suicidal ideation.</li>
<li>Monitor for adverse effects, which include headache, weakness, sedation, dizziness, insomnia; nausea, constipation, or diarrhea;
            dry mouth; sweating; male ejaculatory disturbance. These occur in more than 10% of all patients and may result in poor
            compliance with drug regimen.
         </li>
<li>Monitor older adult for fluid and sodium imbalances.</li>
<li>Monitor those 
         </li><li>Monitor for significant weight loss.</li>
<li>Monitor patients with history of mania for reactivation of condition.</li>
<li>Monitor patients with preexisting cardiovascular disease carefully because paroxetine may adversely affect hemodynamic status.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use caution when operating hazardous machinery or equipment until response to drug is known.</li>
<li>Concurrent use of alcohol may increase risk of adverse CNS effects.</li>
<li>Adaptation to some adverse effects (especially dizziness and nausea) may occur over a period of 46 wk.</li>
<li>Do not stop drug therapy after improvement in emotional status occurs.</li>
<li>Notify physician of any distressing adverse effects.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>